Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$34.56
+0.06 (+0.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-18.0M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
93.4x
↑EV/EBITDA
36.9x
↑ROE
4.0%
↑Gross Margin
82.5%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.4%
FCF CAGR
—
FCF margin
2.3%
FCF / Net income
0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $671.0M · net income $42.1M · FCF $15.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $671.0M | $671.0M | $504.4M | $517.8M | $526.5M |
| Net Income | $42.1M | $42.1M | $40.2M | $36.3M | $32.4M |
| EBITDA | $118.5M | $118.5M | $102.9M | $99.5M | $84.2M |
| EPS | 0.35 | 0.35 | 0.34 | 0.30 | 0.27 |
| Gross Margin | 82.5% | 82.5% | 83.2% | 81.3% | 75.3% |
| Operating Margin | 13.4% | 13.4% | 11.9% | 10.4% | 8.5% |
| Net Margin | 6.3% | 6.3% | 8.0% | 7.0% | 6.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.31 | 0.27 | 0.19 |
| Current Ratio | 1.07 | 1.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.4M | $15.4M | $-18.0M | $-173.3M | $-224.8M |
| Returns | |||||
| ROE | 4.0% | 4.0% | 3.9% | 3.7% | 3.4% |
| Valuation | |||||
| P/E | 93.41 | 93.41 | 58.76 | 75.71 | 114.13 |
| EV/EBITDA | 36.86 | 36.86 | 25.57 | 29.88 | 44.98 |
| P/B | 3.94 | 3.94 | 2.31 | 2.78 | 3.90 |
| Growth & Yield | |||||
| Revenue Growth | 33.0% | 33.0% | -2.6% | -1.6% | — |
| EPS Growth | 4.6% | 4.6% | 10.7% | 11.9% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
106.1%
EPS terminal req.
$3.07
Spread vs growth
-101.5%
5Y implied EPS CAGR
60.3%
EPS terminal req.
$3.71
Spread vs growth
-55.7%
10Y implied EPS CAGR
32.8%
EPS terminal req.
$5.98
Spread vs growth
-28.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+49.3%
Start / end P/E
69.2x → 98.6x
EPS bridge
0.34 → 0.35
Residual
+2.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.